Literature DB >> 33209497

An alternative splicing signature model for predicting hepatocellular carcinoma-specific survival.

Sheng Dong1, Li-Jun Lu1.   

Abstract

BACKGROUND: Alternative splicing (AS) is a transcriptional regulation mechanism, which can expand the coding ability of genome and contribute to the occurrence and development of cancer. A systematic analysis of AS in hepatocellular carcinoma (HCC) is lacking and urgently needed.
METHODS: Univariate and multivariate Cox regression analyses were used to distinguish survival-related AS events and to calculate the risk score. Kaplan-Meier analysis and receiver operating characteristic (ROC) curves were used to evaluate the AS events' clinical significance to build a risk model in HCC.
RESULTS: Data of AS events was obtained from the Splice-Seq database. The corresponding clinical information of HCC was downloaded from The Cancer Genome Atlas (TCGA) data portal. We analyzed 78,878 AS events from 13,045 genes in HCC patients. A total of 2,440 and 2,888 AS events were significantly related to HCC patients' disease-free survival (DFS) and overall survival (OS). The two prognostic models (DFS and OS) were constructed based on a total of seven AS types from survival-related AS events above. The area under the curve (AUC) of the ROC curves was 0.769 in the DFS cohort and 0.886 in the OS cohort.
CONCLUSIONS: The prognostic model constructed by AS events can be used to predict the prognosis of HCC patients and provide potential therapeutic targets for further validation. 2020 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); alternative splicing (AS); gene analysis; prognosis

Year:  2020        PMID: 33209497      PMCID: PMC7657838          DOI: 10.21037/jgo-20-377

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  36 in total

1.  Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing.

Authors:  Qun Pan; Ofer Shai; Leo J Lee; Brendan J Frey; Benjamin J Blencowe
Journal:  Nat Genet       Date:  2008-11-02       Impact factor: 38.330

2.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

Review 3.  The role of high-throughput technologies in clinical cancer genomics.

Authors:  Saad F Idris; Saif S Ahmad; Michael A Scott; George S Vassiliou; James Hadfield
Journal:  Expert Rev Mol Diagn       Date:  2013-03       Impact factor: 5.225

4.  Intratumor heterogeneity in hepatocellular carcinoma.

Authors:  Juliane Friemel; Markus Rechsteiner; Lukas Frick; Friederike Böhm; Kirsten Struckmann; Michèle Egger; Holger Moch; Mathias Heikenwalder; Achim Weber
Journal:  Clin Cancer Res       Date:  2014-09-23       Impact factor: 12.531

5.  SpliceSeq: a resource for analysis and visualization of RNA-Seq data on alternative splicing and its functional impacts.

Authors:  Michael C Ryan; James Cleland; RyangGuk Kim; Wing Chung Wong; John N Weinstein
Journal:  Bioinformatics       Date:  2012-07-20       Impact factor: 6.937

6.  An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.

Authors:  Jianfang Liu; Tara Lichtenberg; Katherine A Hoadley; Laila M Poisson; Alexander J Lazar; Andrew D Cherniack; Albert J Kovatich; Christopher C Benz; Douglas A Levine; Adrian V Lee; Larsson Omberg; Denise M Wolf; Craig D Shriver; Vesteinn Thorsson; Hai Hu
Journal:  Cell       Date:  2018-04-05       Impact factor: 41.582

7.  Intron-centric estimation of alternative splicing from RNA-seq data.

Authors:  Dmitri D Pervouchine; David G Knowles; Roderic Guigó
Journal:  Bioinformatics       Date:  2012-11-21       Impact factor: 6.937

8.  Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma.

Authors: 
Journal:  Cell       Date:  2017-06-15       Impact factor: 66.850

Review 9.  Aberrant alternative splicing is another hallmark of cancer.

Authors:  Michael Ladomery
Journal:  Int J Cell Biol       Date:  2013-09-11

10.  TCGASpliceSeq a compendium of alternative mRNA splicing in cancer.

Authors:  Michael Ryan; Wing Chung Wong; Robert Brown; Rehan Akbani; Xiaoping Su; Bradley Broom; James Melott; John Weinstein
Journal:  Nucleic Acids Res       Date:  2015-11-23       Impact factor: 16.971

View more
  2 in total

1.  Identification of a Novel Four-Gene Signature Correlated With the Prognosis of Patients With Hepatocellular Carcinoma: A Comprehensive Analysis.

Authors:  Weihua Zhu; Lixin Ru; Zhenchao Ma
Journal:  Front Oncol       Date:  2021-03-12       Impact factor: 6.244

2.  Ral GEF with the PH Domain and SH3 Binding Motif 1 Regulated by Splicing Factor Junction Plakoglobin and Pyrimidine Metabolism Are Prognostic in Uterine Carcinosarcoma.

Authors:  Hongjun Guo; Siqiao Wang; Aiqing Xie; Wenhuizi Sun; Chenlu Wei; Shuyuan Xian; Huabin Yin; Mingxiao Li; Hanlin Sun; Hong Li; Tong Meng; Jie Zhang; Zongqiang Huang
Journal:  Dis Markers       Date:  2021-10-28       Impact factor: 3.434

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.